AbbVie Inc.
ABBV
$166.41
$1.751.06%
| Weiss Ratings | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Fair | |||
| Risk Grade | C- | |||
| Reward Grade | B | |||
| Rating Factors | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Good | |||
| Growth Index | Weak | |||
| Efficiency Index | Excellent | |||
| Solvency Index | Good | |||
| Total Return Index | Good | |||
| Volatility Index | Good | |||
| Beta / Standard Deviation | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.32 | |||
| Price History | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -0.60% | |||
| 30-Day Total Return | -7.02% | |||
| 60-Day Total Return | 2.34% | |||
| 90-Day Total Return | 12.79% | |||
| Year to Date Total Return | 5.23% | |||
| 1-Year Total Return | 4.40% | |||
| 2-Year Total Return | 8.07% | |||
| 3-Year Total Return | 61.66% | |||
| 5-Year Total Return | 144.31% | |||
| 52-Week High % Change | -9.97% | |||
| 52-Week Low % Change | 25.73% | |||
| Price | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $182.89 | |||
| 52-Week Low Price | $130.96 | |||
| 52-Week Low Price (Date) | Jun 28, 2023 | |||
| 52-Week High Price (Date) | Mar 12, 2024 | |||
| Valuation | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 291.55B | |||
| Enterprise Value | 339.35B | |||
| Price/Earnings (TTM) | 60.41 | |||
| Earnings Per Share (TTM) | 2.73 | |||
| Earnings Per Share Growth | -58.85% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 5.37 | |||
| Price/Book (Q) | 28.07 | |||
| Enterprise Value/Revenue (TTM) | 6.25 | |||
| Price | $168.02 | |||
| Enterprise Value/EBITDA (TTM) | 14.42 | |||
| Enterprise Value/EBIT | 22.87 | |||
| Market Cap Category | Mega Cap | |||
| Dividends and Shares | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.77B | |||
| Dividend Yield | 3.68% | |||
| Div. Per Share (Most Recent) | $1.55 | |||
| Dividend Per Share (TTM) | $6.06 | |||
| Payout Ratio (TTM) | 216.72% | |||
| Dividend Per Share (Most Recent) | $1.55 | |||
| Company Info | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 847 932 7900 | |||
| Address | 1 North Waukegan Road North Chicago, IL 60064-6400 | |||
| Website | www.abbvie.com | |||
| Country | United States | |||
| Year Founded | 2012 | |||
| Profitability | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 27.31% | |||
| Profit Margin | 8.95% | |||
| Management Effectiveness | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 6.78% | |||
| Return on Equity | 35.20% | |||
| Income Statement | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 54.32B | |||
| Total Revenue (TTM) | 54.32B | |||
| Revenue Per Share | $30.65 | |||
| Gross Profit (TTM) | 35.40B | |||
| EBITDA (TTM) | 23.53B | |||
| EBIT (TTM) | 14.84B | |||
| Net Income (TTM) | 4.86B | |||
| Net Income Avl. to Common (TTM) | 4.86B | |||
| Total Revenue Growth (Q YOY) | -5.42% | |||
| Earnings Growth (Q YOY) | -66.67% | |||
| EPS Diluted (TTM) | 2.73 | |||
| EPS Diluted Growth (Q YOY) | -66.95% | |||
| Balance Sheet | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 12.82B | |||
| Cash Per Share (Q) | $7.23 | |||
| Total Current Assets (Q) | 33.00B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 10.40B | |||
| Current Ratio (Q) | 0.872 | |||
| Book Value Per Share (Q) | $5.87 | |||
| Total Assets (Q) | 134.71B | |||
| Total Current Liabilities (Q) | 37.84B | |||
| Total Debt (Q) | 60.58B | |||
| Total Liabilities (Q) | 124.31B | |||
| Total Common Equity (Q) | 10.36B | |||
| Cash Flow | ABBV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -2.01B | |||
| Cash from Financing (TTM) | -17.22B | |||
| Net Change in Cash (TTM) | 3.61B | |||
| Levered Free Cash Flow (TTM) | 20.86B | |||
| Cash from Operations (TTM) | 22.84B | |||
